Notice: This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CERC vs. CPRX, MLTX, MRUS, ARWR, HCM, EWTX, MIRM, AMRX, GMTX, and PTGXShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), Gemini Therapeutics (GMTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "medical" sector. Cerecor vs. Catalyst Pharmaceuticals MoonLake Immunotherapeutics Merus Arrowhead Pharmaceuticals HUTCHMED Edgewise Therapeutics Mirum Pharmaceuticals Amneal Pharmaceuticals Gemini Therapeutics Protagonist Therapeutics Cerecor (NASDAQ:CERC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Is CERC or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 31.01% compared to Cerecor's net margin of -1,194.82%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Cerecor's return on equity.Company Net Margins Return on Equity Return on Assets Cerecor-1,194.82% -261.82% -133.96% Catalyst Pharmaceuticals 31.01%40.79%34.87% Does the media prefer CERC or CPRX? In the previous week, Catalyst Pharmaceuticals had 4 more articles in the media than Cerecor. MarketBeat recorded 4 mentions for Catalyst Pharmaceuticals and 0 mentions for Cerecor. Catalyst Pharmaceuticals' average media sentiment score of 0.65 beat Cerecor's score of 0.16 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Cerecor Neutral Catalyst Pharmaceuticals Positive Which has more volatility & risk, CERC or CPRX? Cerecor has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Do analysts rate CERC or CPRX? Catalyst Pharmaceuticals has a consensus price target of $32.25, suggesting a potential upside of 49.13%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Cerecor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerecor 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has better earnings & valuation, CERC or CPRX? Catalyst Pharmaceuticals has higher revenue and earnings than Cerecor. Cerecor is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerecor$6.70M120.94-$63.50M-$0.57-14.81Catalyst Pharmaceuticals$398.20M6.48$71.41M$1.1818.33 Do institutionals and insiders hold more shares of CERC or CPRX? 62.8% of Cerecor shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 45.7% of Cerecor shares are held by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor CERC or CPRX? Catalyst Pharmaceuticals received 315 more outperform votes than Cerecor when rated by MarketBeat users. Likewise, 74.96% of users gave Catalyst Pharmaceuticals an outperform vote while only 74.00% of users gave Cerecor an outperform vote. CompanyUnderperformOutperformCerecorOutperform Votes18574.00% Underperform Votes6526.00% Catalyst PharmaceuticalsOutperform Votes50074.96% Underperform Votes16725.04% SummaryCatalyst Pharmaceuticals beats Cerecor on 16 of the 19 factors compared between the two stocks. Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$810.32M$7.05B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-14.815.9726.4719.17Price / Sales120.94268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book38.366.707.644.62Net Income-$63.50M$138.76M$3.19B$246.06M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$8.44+17.9%N/A+67.7%$810.32M$6.70M-14.8131Gap UpCPRXCatalyst Pharmaceuticals4.8648 of 5 stars$23.27+0.0%$32.25+38.6%+57.7%$2.78B$398.20M19.7280MLTXMoonLake Immunotherapeutics2.0732 of 5 stars$43.21-0.9%$85.50+97.9%-21.0%$2.76BN/A-33.502News CoverageGap UpMRUSMerus2.9171 of 5 stars$40.20-0.2%$85.92+113.7%+5.3%$2.75B$43.95M-10.1837ARWRArrowhead Pharmaceuticals4.096 of 5 stars$19.95+4.4%$41.44+107.7%-31.8%$2.50B$3.55M-3.97400HCMHUTCHMED1.5944 of 5 stars$13.80+4.4%$19.00+37.7%+11.3%$2.41B$838M0.001,760News CoverageGap UpEWTXEdgewise Therapeutics1.6533 of 5 stars$25.39-2.4%$41.29+62.6%+54.7%$2.40BN/A-16.9360MIRMMirum Pharmaceuticals2.6993 of 5 stars$50.04-1.3%$57.10+14.1%+85.6%$2.40B$186.37M-24.77140News CoverageAMRXAmneal Pharmaceuticals3.7675 of 5 stars$7.73-2.3%$10.00+29.4%+36.6%$2.40B$2.39B-11.377,700Positive NewsGMTXGemini TherapeuticsN/A$54.10flatN/A-18.2%$2.34BN/A-54.1030News CoveragePTGXProtagonist Therapeutics3.806 of 5 stars$38.670.0%$56.00+44.8%+44.7%$2.30B$60M14.54120Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap Up Related Companies and Tools Related Companies Catalyst Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Merus Alternatives Arrowhead Pharmaceuticals Alternatives HUTCHMED Alternatives Edgewise Therapeutics Alternatives Mirum Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Protagonist Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CERC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
